Advancing nanotechnology for neoantigen-based cancer theranostics

Zou, Jianhua; Zhang, Yu; Pan, Yuanbo; Mao, Zhengwei; Chen, Xiaoyuan

doi:10.1039/d3cs00162h

Cited by 3 publications

(1 citation statement)

References 193 publications

(384 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advent of next-generation sequencing technologies enables the widespread investigation of alternative splicing events in cancer and the economical identification of tumor-specific neoepitopes in individual patients ( 17 , 18 ). Moreover, the creation of algorithms to predict the binding of epitopes to MHC molecules has facilitated the identification of potentially immunogenic neoepitopes, which may provide fresh perspectives on cancer immunotherapy and is expected to improve the clinical prognosis of cancer patients ( 19 , 20 ). This review offers a comprehensive overview of the origins and biological roles of neoantigens produced by alternative splicing and the clinical uses of neoantigen-based immunotherapy approaches.…”

Section: Introductionmentioning

confidence: 99%

Neoantigens in cancer immunotherapy: focusing on alternative splicing

Huang,

Wen,

Tuerhong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Alternative splicing (AS) functions as a crucial program in transcriptional modulation, leading to proteomic diversity and functional alterations of proteins. These splicing actions induce various neoantigens that hold prognostic significance and contribute to various aspects of cancer progression, including immune responses against cancer. The advent of immunotherapy has remarkably revolutionized tumor therapy. In this regard, AS-derived neoantigens are potent targets for cancer vaccines and chimeric antigen receptor (CAR) T cell therapies. In this review, we outline that AS-derived neoantigens serve as promising immunotherapeutic targets and guide immunotherapy strategies. This evidence contributes to a deeper comprehension of the complexity of proteomic diversity and provides novel perspectives and techniques for precision medicine in immunotherapy. Moreover, we underscore the obstacles that are awaited to be addressed for this novel approach to become clinically applicable.

show abstract

Section: Introductionmentioning

confidence: 99%

Neoantigens in cancer immunotherapy: focusing on alternative splicing

Huang,

Wen,

Tuerhong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Self‐Oxygenated Hydrogel Enhances Immune Cell Response and Infiltration Via Triggering Dual DNA Damage to Activate cGAS‐STING and Inhibiting CAFs

Tian,

Zhu,

Wang

et al. 2024

Small

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) offer promise in breaking through the treatment and survival dilemma of triple‐negative breast cancer (TNBC), yet only immunomodulatory subtype and ≈5% TNBC patients respond as monotherapy due to lack of effector immune cells (internal problem) and physical barrier (external limitation) formed by cancer‐associated fibroblasts (CAFs). A hydrogel drug‐delivery platform, ALG@TBP‐2/Pt(0)/nintedanib (ALG@TPN), is designed to induce strong immune functions and the dual elimination of the internal and external tumor microenvironment (TME). Activated by white light, through type I and II photodynamic therapy (PDT), TBP‐2 generates large amounts of reactive oxygen species (ROS) intracellularly, oxidizing mitochondrial DNA (mtDNA). The unique catalase activity of Pt(0) converts endogenous H2O2 to O2, reducing the anoxia‐limiting PDT and enhancing ROS generation efficacy. Abundant ROS can oxidize Pt(0) to cytotoxic Pt(II), damaging the nuclear DNA (nDNA). Dual damage to mtDNA and nDNA might bi‐directionally activate the cGAS/STING pathway and enhance the immune cell response. Besides, nintedanib demonstrates a significant inhibitory effect on CAFs, weakening the immune barrier and deepening immune cell infiltration. Overall, the study provides a self‐oxygenating hydrogel with the “PDT/chemotherapy/anti‐CAFs” effect, triggering the cGAS/STING pathway to reshape the TME. Both internal and external interventions increase anti‐TNBC immune responses.

show abstract

Polyphenol-based polymer nanoparticles for inhibiting amyloid protein aggregation: recent advances and perspectives

Fang,

Zhang,

Liu

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

Polyphenols are a group of naturally occurring compounds that possess a range of biological properties capable of potentially mitigating or preventing the progression of age-related cognitive decline and Alzheimer’s disease (AD). AD is a chronic neurodegenerative disease known as one of the fast-growing diseases, especially in the elderly population. Moreover, as the primary etiology of dementia, it poses challenges for both familial and societal structures, while also imposing a significant economic strain. There is currently no pharmacological intervention that has demonstrated efficacy in treating AD. While polyphenols have exhibited potential in inhibiting the pathological hallmarks of AD, their limited bioavailability poses a significant challenge in their therapeutic application. Furthermore, in order to address the therapeutic constraints, several polymer nanoparticles are being explored as improved therapeutic delivery systems to optimize the pharmacokinetic characteristics of polyphenols. Polymer nanoparticles have demonstrated advantageous characteristics in facilitating the delivery of polyphenols across the blood–brain barrier, resulting in their efficient distribution within the brain. This review focuses on amyloid-related diseases and the role of polyphenols in them, in addition to discussing the anti-amyloid effects and applications of polyphenol-based polymer nanoparticles.

show abstract

Advancing nanotechnology for neoantigen-based cancer theranostics

Abstract: Developing nanotechnology for neoantigen-based precision therapy, including photodynamic therapy, photothermal therapy, radiotherapy, chemo/chemodynamic therapy, immunotherapy, and other therapies.

Cited by 3 publications

References 193 publications

Neoantigens in cancer immunotherapy: focusing on alternative splicing

Neoantigens in cancer immunotherapy: focusing on alternative splicing

Self‐Oxygenated Hydrogel Enhances Immune Cell Response and Infiltration Via Triggering Dual DNA Damage to Activate cGAS‐STING and Inhibiting CAFs

Polyphenol-based polymer nanoparticles for inhibiting amyloid protein aggregation: recent advances and perspectives

Contact Info

Product

Resources

About